Optimi Health to Court Institutional Investors at Sidoti Micro-Cap Conference

Optimi Health ( (TSE:OPTI) ) has shared an announcement.

Optimi Health Corp. will present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026, where CEO Dane Stevens is scheduled to host a virtual presentation and one-on-one meetings with institutional investors. By engaging directly with the investment community at a dedicated micro-cap forum, the company is seeking to raise its profile among institutional investors and potentially broaden its shareholder base as it advances its position in the emerging market for regulated psychedelic-based mental health treatments.

The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.

Spark’s Take on TSE:OPTI Stock

According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.

Optimi Health’s overall score is primarily impacted by its financial performance, which shows potential but is hindered by persistent losses and cash flow challenges. Technical analysis provides some positive momentum signals, but valuation concerns due to negative earnings weigh heavily on the score.

To see Spark’s full report on TSE:OPTI stock, click here.

More about Optimi Health

Optimi Health Corp. is a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer specializing in prescribed psychedelic treatments for mental health therapies. Operating from two 10,000-square-foot facilities in British Columbia, the company produces validated MDMA and botanical psilocybin products, supplying active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently available for prescription use in Australia and accessible in Canada through special access pathways.

Average Trading Volume: 66,980

Technical Sentiment Signal: Buy

Current Market Cap: C$30.44M

See more insights into OPTI stock on TipRanks’ Stock Analysis page.